Organogenesis (NASDAQ:ORGO) Trading Down 5.8% – Time to Sell?

Organogenesis Holdings Inc. (NASDAQ:ORGO)’s share price dropped 5.8% during mid-day trading on Wednesday . The stock traded as low as $5.02 and last traded at $4.92. Approximately 202,237 shares were traded during trading, a decline of 81% from the average daily volume of 1,088,569 shares. The stock had previously closed at $5.22.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley raised their target price on shares of Organogenesis from $4.00 to $6.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 5th.

Organogenesis Price Performance

The firm has a 50-day simple moving average of $4.19 and a 200-day simple moving average of $3.56. The firm has a market cap of $592.29 million, a P/E ratio of -77.83 and a beta of 1.66. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21.

Insider Buying and Selling

In other news, Director Michael Joseph Driscoll sold 25,000 shares of Organogenesis stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total value of $127,500.00. Following the transaction, the director now owns 166,879 shares of the company’s stock, valued at $851,082.90. The trade was a 13.03 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 36.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Organogenesis

Several institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP lifted its holdings in shares of Organogenesis by 5.2% during the 4th quarter. Wellington Management Group LLP now owns 254,282 shares of the company’s stock valued at $814,000 after purchasing an additional 12,634 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its position in Organogenesis by 16.5% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 39,159 shares of the company’s stock valued at $125,000 after buying an additional 5,551 shares in the last quarter. Mackenzie Financial Corp raised its stake in Organogenesis by 255.1% in the fourth quarter. Mackenzie Financial Corp now owns 76,353 shares of the company’s stock valued at $244,000 after buying an additional 54,850 shares during the last quarter. Soleus Capital Management L.P. boosted its holdings in Organogenesis by 5.4% in the fourth quarter. Soleus Capital Management L.P. now owns 12,484,876 shares of the company’s stock worth $39,952,000 after acquiring an additional 645,000 shares in the last quarter. Finally, Virtus Investment Advisers Inc. purchased a new stake in shares of Organogenesis during the fourth quarter worth about $157,000. 49.57% of the stock is currently owned by institutional investors and hedge funds.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.